[Federal Register Volume 59, Number 92 (Friday, May 13, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-11641]


[[Page Unknown]]

[Federal Register: May 13, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Advisory Committee Meeting; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is announcing an amendment to 
the notice of a meeting of the Biological Response Modifiers Advisory 
Committee which is scheduled for May 25 and 26, 1994. This meeting was 
announced in the Federal Register of April 15, 1994 (59 FR 18134 at 
18135). The amendment is being made to remove one agenda item and to 
remove the closed committee deliberations portion from the meeting. 
There are no other changes. This amendment will be announced at the 
beginning of the open portion of the meeting.

FOR FURTHER INFORMATION CONTACT: William Freas or Pearline Muckelvene, 
Center for Biologics Evaluation and Research (HFM-21), Food and Drug 
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-594-1054.

SUPPLEMENTARY INFORMATION: In the Federal Register of April 15, 1994, 
FDA announced that a meeting of the Biological Response Modifiers 
Advisory Committee would be held on May 25 and 26, 1994. On page 18135, 
in the third column, under ``Type of meeting and contact person'' and 
``Open committee discussion'' portions of the agenda are amended to 
read as follows:
    Type of meeting and contact person. Open public hearing, May 25, 
1994, 10:30 a.m. to 11:15 a.m., unless public participation does not 
last that long; open committee discussion, 11:15 a.m. to 5:30 p.m.; 
open public hearing, May 26, 1994, 8 a.m. to 8:45 a.m., unless public 
participation does not last that long; open committee discussion, 8:45 
a.m. to 3 p.m.; William Freas or Pearline Muckelvene, Center for 
Biologics Evaluation and Research (HFM-21), Food and Drug 
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-594-1054.
    Open committee discussion. The committee will discuss issues 
related to the safety and efficacy of hematopoietic support regimens in 
the setting of myelotoxic chemotherapy.

    Dated: May 9, 1994.
Linda A. Suydam,
Interim Deputy Commissioner for Operations.
[FR Doc. 94-11641 Filed 5-12-94; 8:45 am]
BILLING CODE 4160-01-F